C

CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765

Watchlist Manager
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Watchlist
Price: 27.34 CNY 2.01% Market Closed
Market Cap: 73.1B CNY
Have any thoughts about
CSPC Innovation Pharmaceutical Co Ltd?
Write Note

CSPC Innovation Pharmaceutical Co Ltd
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CSPC Innovation Pharmaceutical Co Ltd
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Accrued Liabilities
ÂĄ48.3m
CAGR 3-Years
56%
CAGR 5-Years
38%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Accrued Liabilities
ÂĄ2B
CAGR 3-Years
2%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Accrued Liabilities
ÂĄ620.1m
CAGR 3-Years
74%
CAGR 5-Years
53%
CAGR 10-Years
31%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Accrued Liabilities
ÂĄ128.5m
CAGR 3-Years
456%
CAGR 5-Years
130%
CAGR 10-Years
63%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Accrued Liabilities
ÂĄ1.5B
CAGR 3-Years
74%
CAGR 5-Years
54%
CAGR 10-Years
46%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Accrued Liabilities
ÂĄ146m
CAGR 3-Years
-11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

CSPC Innovation Pharmaceutical Co Ltd
Glance View

Market Cap
73.1B CNY
Industry
Pharmaceuticals

Nestled in the dynamic landscape of the pharmaceutical industry, CSPC Innovation Pharmaceutical Co Ltd stands as a beacon of innovation and ambition. Evolving from its roots in traditional pharmaceutical practices, the company has carved out a niche for itself by embracing cutting-edge research and development methodologies. At the core of their operations is an unwavering commitment to creating novel drugs that target complex medical challenges. This commitment is propelled by their significant investment in state-of-the-art R&D facilities and collaborations with leading academic institutions and biotech firms. By fostering a rich pipeline of new drugs, CSPC Innovation strives to maintain its competitive edge in a rapidly changing market, driven by both pressing healthcare needs and technological advancements. The company leverages its robust distribution network to bring these innovations to market, drawing upon a diverse portfolio that includes drugs for therapeutic areas such as oncology, cardiovascular health, and metabolic disorders. Revenue generation, therefore, hinges largely on the successful commercialization of these pharmaceutical products, through both direct sales and strategic partnerships. Additionally, CSPC Innovation engages in manufacturing and selling Active Pharmaceutical Ingredients (APIs), further diversifying its income streams. By balancing risk and opportunity, the company not only aims to meet the immediate health demands of its consumer base but also positions itself to capture long-term growth within the global healthcare sector, ensuring a steady influx of revenue and sustainability for future endeavors.

Intrinsic Value
19.15 CNY
Overvaluation 30%
Intrinsic Value
Price
C

See Also

What is CSPC Innovation Pharmaceutical Co Ltd's Accrued Liabilities?
Accrued Liabilities
48.3m CNY

Based on the financial report for Sep 30, 2024, CSPC Innovation Pharmaceutical Co Ltd's Accrued Liabilities amounts to 48.3m CNY.

What is CSPC Innovation Pharmaceutical Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
38%

Over the last year, the Accrued Liabilities growth was 61%. The average annual Accrued Liabilities growth rates for CSPC Innovation Pharmaceutical Co Ltd have been 56% over the past three years , 38% over the past five years .

Back to Top